Intercalated Dosing Schedule of Erlotinib and Docetaxel as a Therapeutic Strategy to Avoid Antagonism and Optimize Its Benefits in Advanced Non–Small-Cell Lung Cancer. A Randomized Phase II Clinical Trial

Óscar Juan, Francisco Aparisi, Alfredo Sánchez-Hernández, José Muñoz-Langa, G. Esquerdo, José García-Sánchez, Antonio López, J. Garde, V. Giner

Clinical Lung Cancer · 2014 · 14 citations · 22 references

Concepts

References

22